Jeff Carr, MMS President, stated, “The success of this program is a strong validation of MMS’ unique technology. MMS is now pursuing additional compelling clinical applications and industry collaboration."
Portland, ME (PRWEB) July 13, 2011
Meridian Medical Systems (MMS) licensed its unique technology to Advanced Cardiac Therapeutics, Inc. (ACT) for the development of a first of its kind, temperature-sensing, saline irrigated ablation catheter for use in the treatment of cardiac arrhythmias.
Catheter ablation of the heart is a procedure used to treat a variety of arrhythmias, and is accomplished by threading a thin catheter through a major blood vessel into the heart under x-ray guidance. The temperature of the tissue during ablation is critical to the procedure -- too low will result in under treatment, too high will result in overtreatment.
The ACT TEMPASURE™ system has been designed to result in improved outcomes for patients by reducing the overall procedure time, and allowing the surgeon to avoid the rare, but serious adverse effects. MMS’ unique passive, microwave radiometry-sensing technology allows the electro physiologist to measure the temperature of target cardiac tissue at depth in the heart wall during the ablation procedure, allowing optimal energy delivery and lesion control.
ACT recently announced that it has received European CE Mark following the first patients having been enrolled and treated in a clinical trial of the safety and performance of the TEMPASURE™ Cardiac Ablation Catheter. The TEMPASURE™ System is the world’s first RF cardiac ablation catheter to offer both saline irrigation and temperature sensing capabilities.
Yves Vandekerckhove, M.D., Chairman of the Department of Cardiology at Sint Jan Hospital in Bruges, Belgium, and who performed the first-ever procedure with the system, stated, “I found the ACT system straightforward to use, requiring no different handling or additional training. Even in the first few patients, we were able to see clinical therapeutic outcomes that closely matched the temperature measurements. The patients I have treated are doing very well.”
Karl-Heinz Kuck, M.D., head of the Department of Cardiology at St. Georg Hospital in Germany and co-principal investigator of the trial stated, “I’m very excited about the promise of this new technology to increase the safety and success of the cardiac ablation procedures.”
The development of ACT’s TEMPASURE™ Cardiac Ablation Catheter, which includes MMS microwave radiometric-sensing technology, is the culmination of over 20 years of ablation research that began with a Small Business Innovative Research Grant from the NIH, awarded in 1991 to Kenneth L. Carr founder and CEO of MMS, and co-founder of ACT.
About Meridian Medical Systems, LLC (MMS),
Headquartered in Portland, Maine USA, privately held Meridian Medical Systems, LLC (MMS) develops specialized systems using its proprietary microwave radiometric-sensing technology.